SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024
Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Exercise as a modulator of purinergic signaling and inflammation in cancer-associated sarcopenia: a narrative review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Circulating muscle- and inflammation-related microRNAs in breast cancer survivorship: associations with subtype, treatment, timing, and age.Molecular biology reports · 2026Article
- Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.Tomography (Ann Arbor, Mich.) · 2026Article
- Characterization of body composition dynamics throughout treatment in patients with early-stage breast cancer.NPJ breast cancer · 2026Article
- Association of low muscle mass and obesity with mortality and cardiovascular outcomes in breast cancer: a population-based study.Breast cancer research and treatment · 2026Article
- Skeletal Muscle Mass in Women With Breast Cancer: Evaluation of Agreement Between Different Methods.Journal of nutrition and metabolism · 2026Article
- The impact of sarcopenia and body mass index on treatment toxicity and survival in patients with extranodal natural killer/T-cell lymphoma: a retrospective analysis.Frontiers in oncology · 2026Article
- Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.Frontiers in oncology · 2026Review
- Sarcopenia and inflammatory markers in early-stage breast cancer: a retrospective case-control study of NLR, MLR, RDW-CV, and HRR in middle-aged and elderly women.Frontiers in surgery · 2026Article
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- Visceral and Subcutaneous Fat Deposits Exhibit Distinct Roles in the Initiation and Progression of Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer.Medicina (Kaunas, Lithuania) · 2025Article
- Prehabilitation Prior to Chemotherapy in Humans: A Review of Current Evidence and Future Directions.Cancers · 2025Review
- Article
- Personalised screening tool for early detection of sarcopenia in stroke patients: a machine learning-based comparative study.Aging clinical and experimental research · 2025Article
- Grip-Strength-Lean-Mass Index (GSLMI) as a valuable tool for sarcopenia diagnosis and survival prognosis in cancer patients: a nationwide multicenter cohort study.The journal of nutrition, health & aging · 2025Article
- Mechanisms, assessment, and exercise interventions for skeletal muscle dysfunction post-chemotherapy in breast cancer: from inflammation factors to clinical practice.Frontiers in oncology · 2025Review
- Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?Breast (Edinburgh, Scotland) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe impact of sarcopenia in oncology is increasingly recognized, yet little is known about its clinical implications in breast cancer. This systematic review and meta-analysis estimates the overall prevalence of sarcopenia in breast cancer, quantifies skeletal muscle index (SMI), and comprehensively evaluates sarcopenia's impact on clinical outcomes.
methodsWe systematically searched primary original research published before June 2023 in four databases: the Cochrane Library via Wiley, CINAHL Plus with Full Text, Embase via Elsevier Excerpta Medica, and Medline via Ovid. Standardized mean SMI and 95% confidence interval (CI) were calculated by applying the random-effects model. The methodological quality of the included studies was assessed using the National Institutes of Health quality assessment checklist.
resultsThe systematic review included 17 studies with a total of 9863 patients; the meta-analysis included 12 of these studies. The mean prevalence of sarcopenia in breast cancer (stages I-III) was 32.5%. The mean SMI assessed by CT was 43.94 cm
conclusionSarcopenia is not just a state of muscle mass loss, but an influencing factor on therapeutic effects and survival rates in oncology. It is thus necessary to recognize the risk of sarcopenia throughout the trajectory of cancer treatment, identify low muscle mass early, and manage it from a prehabilitation perspective.
Indexed as
Identifiers
38702479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.